Goldschmidt, Hartmut
Dimopoulos, Meletios A.
Rajkumar, S. Vincent
Weisel, Katja C.
Moreau, Philippe
Chng, Wee-Joo
Mikala, Gábor
Cavo, Michele
Ramasamy, Karthik
Suryanarayan, Kaveri
Teng, Zhaoyang
Labotka, Richard
Mateos, Maria Victoria http://orcid.org/0000-0003-2390-1218
Funding for this research was provided by:
Takeda Pharmaceutical Company
Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited
Article History
Received: 19 December 2019
Revised: 12 March 2020
Accepted: 27 March 2020
First Online: 23 April 2020
Compliance with ethical standards
:
: The TOURMALINE-MM3 study was funded by Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. Prof Goldschmidt has served on the advisory boards of Adaptive Biotechnology, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Sanofi, and Takeda; has received research funding from Amgen, Bristol-Myers Squibb, Celgene, Chugai, Janssen, Sanofi, Mundipharma, Molecular Partners, MSD, Takeda, and Novartis; has received honoraria from ArtTempi, Bristol-Myers Squibb, Celgene, Chugai, Janssen, Novartis and Sanofi; and has received Grants and/or provision of Investigational Medicinal Product (IMP) from Celgene, Janssen, Chugai, BMS, Sanofi, Amgen, Dietmar Hopp, and John Hopkins University. Prof Dimopoulos has received research funding from Genesis Pharma; has acted as a consultant for, and received honoraria from Novartis, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Onyx Pharmaceuticals, and Takeda Oncology; and has served on the advisory committees of Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Onyx Pharmaceuticals, and Takeda Oncology. Prof Rajkumar received research funding to his institution for this trial. Dr Weisel has served on the advisory boards of Amgen, Bristol-Myers Squibb, Adaptive Biotech, Celgene, Janssen, Juno, Takeda, and Sanofi; has received honoraria from Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda; and has received research funding from Amgen, Celgene, Janssen, and Sanofi. Prof Moreau has received personal fees from Takeda, Celgene, Janssen, and Amgen. Prof Chng has received honoraria from Takeda. Dr Mikala has served on the advisory boards of Amgen, Celgene, Janssen, Roche, Takeda; and has received research funding from AbbVie and Celgene. Prof Cavo has received consultancy fees from Janssen, Celgene, Takeda, Amgen, Bristol-Myers Squibb, and AbbVie. Dr Ramasamy has received research funding from Takeda, Janssen, Amgen, and Celgene; and has received honoraria from Takeda, Amgen, Janssen, Celgene, Adaptive Biotechnology, Abbvie, Sanofi Oncology, and Oncopeptides. Dr Suryanarayan, and Dr Labotka are employees of, and Dr Teng is a previous employee of, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, and is currently employed by Servier Pharmaceuticals. Prof Mateos has received personal fees from Takeda, Janssen, AMGEN, Celgene, GSK, and Abbvie.